These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 25996567)

  • 1. Effect of treatment willingness on specialist assessment and treatment uptake for hepatitis C virus infection among people who use drugs: the ETHOS study.
    Alavi M; Micallef M; Fortier E; Dunlop AJ; Balcomb AC; Day CA; Treloar C; Bath N; Haber PS; Dore GJ; Grebely J;
    J Viral Hepat; 2015 Nov; 22(11):914-25. PubMed ID: 25996567
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment and treatment of hepatitis C virus infection among people who inject drugs in the opioid substitution setting: ETHOS study.
    Alavi M; Grebely J; Micallef M; Dunlop AJ; Balcomb AC; Day CA; Treloar C; Bath N; Haber PS; Dore GJ;
    Clin Infect Dis; 2013 Aug; 57 Suppl 2():S62-9. PubMed ID: 23884068
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of social functioning and living arrangement on treatment intent, specialist assessment and treatment uptake for hepatitis C virus infection among people with a history of injecting drug use: The ETHOS study.
    Fortier E; Alavi M; Micallef M; Dunlop AJ; Balcomb AC; Day CA; Treloar C; Bath N; Haber PS; Dore GJ; Bruneau J; Grebely J;
    Int J Drug Policy; 2015 Nov; 26(11):1094-102. PubMed ID: 26145482
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liver disease knowledge and acceptability of non-invasive liver fibrosis assessment among people who inject drugs in the drug and alcohol setting: The LiveRLife Study.
    Marshall AD; Micallef M; Erratt A; Telenta J; Treloar C; Everingham H; Jones SC; Bath N; How-Chow D; Byrne J; Harvey P; Dunlop A; Jauncey M; Read P; Collie T; Dore GJ; Grebely J
    Int J Drug Policy; 2015 Oct; 26(10):984-91. PubMed ID: 26256938
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment and delivery of treatment for hepatitis C virus infection in an opioid substitution treatment clinic with integrated peer-based support in Newcastle, Australia.
    Keats J; Micallef M; Grebely J; Hazelwood S; Everingham H; Shrestha N; Jones T; Bath N; Treloar C; Dore GJ; Dunlop A;
    Int J Drug Policy; 2015 Oct; 26(10):999-1006. PubMed ID: 26275578
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Knowledge and barriers associated with assessment and treatment for hepatitis C virus infection among people who inject drugs.
    Treloar C; Hull P; Dore GJ; Grebely J
    Drug Alcohol Rev; 2012 Nov; 31(7):918-24. PubMed ID: 22612899
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Potential Reach of Opioid Substitution Settings to Deliver HCV Care to People Who Inject Drugs in Australia.
    Butler K; Day C; Dietze P; Bruno R; Alati R; Burns L
    J Subst Abuse Treat; 2015 Nov; 58():90-4. PubMed ID: 26117080
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Knowledge of hepatitis C and treatment willingness amongst people who inject drugs in an era of direct acting antivirals.
    Mah A; Hull MW; DeBeck K; Milloy MJ; Dobrer S; Nosova E; Wood E; Kerr T; Hayashi K
    Int J Drug Policy; 2017 Sep; 47():137-143. PubMed ID: 28347636
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Depression, Anxiety, and Stress Among People With Chronic Hepatitis C Virus Infection and a History of Injecting Drug Use in New South Wales, Australia.
    Fortier E; Alavi M; Bruneau J; Micallef M; Perram J; Sockalingam S; Dunlop AJ; Balcomb AC; Day CA; Treloar C; Bath N; Haber PS; Dore GJ; Grebely J;
    J Addict Med; 2017; 11(1):10-18. PubMed ID: 27775955
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatitis C virus testing, liver disease assessment and treatment uptake among people who inject drugs pre- and post-universal access to direct-acting antiviral treatment in Australia: The LiveRLife study.
    Bajis S; Grebely J; Hajarizadeh B; Applegate T; Marshall AD; Ellen Harrod M; Byrne J; Bath N; Read P; Edwards M; Gorton C; Hayllar J; Cock V; Peterson S; Thomson C; Weltman M; Jefferies M; Wood W; Haber P; Ezard N; Martinello M; Maher L; Dore GJ;
    J Viral Hepat; 2020 Mar; 27(3):281-293. PubMed ID: 31698545
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association between rapid utilisation of direct hepatitis C antivirals and decline in the prevalence of viremia among people who inject drugs in Australia.
    Iversen J; Dore GJ; Catlett B; Cunningham P; Grebely J; Maher L
    J Hepatol; 2019 Jan; 70(1):33-39. PubMed ID: 30367897
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Estimating the cascade of hepatitis C testing, care and treatment among people who inject drugs in Australia.
    Iversen J; Grebely J; Catlett B; Cunningham P; Dore GJ; Maher L
    Int J Drug Policy; 2017 Sep; 47():77-85. PubMed ID: 28578863
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Short-term injection drug use changes following hepatitis C virus (HCV) assessment and treatment among persons who inject drugs with acute HCV infection.
    Artenie AA; Zang G; Daniel M; Fortier E; Jutras-Aswad D; Puzhko S; Bruneau J
    Int J Drug Policy; 2017 Sep; 47():239-243. PubMed ID: 28587944
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Uptake of hepatitis C treatment among people who inject drugs attending Needle and Syringe Programs in Australia, 1999-2011.
    Iversen J; Grebely J; Topp L; Wand H; Dore G; Maher L
    J Viral Hepat; 2014 Mar; 21(3):198-207. PubMed ID: 24438681
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factors associated with hepatitis C testing, treatment, and current hepatitis C infection among men and women who inject drugs: The ETHOS engage study.
    Valerio H; Marshall AD; Conway A; Treloar C; Carter L; Martinello M; Henderson C; Amin J; Read P; Silk D; Degenhardt L; Prain B; Alavi M; Dore GJ; Grebely J;
    Int J Drug Policy; 2024 May; 127():104394. PubMed ID: 38608357
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Uptake of direct acting antiviral therapies for the treatment of hepatitis C virus among people who inject drugs in a universal health-care system.
    Butler K; Larney S; Day CA; Burns L
    Drug Alcohol Rev; 2019 Mar; 38(3):264-269. PubMed ID: 30548702
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Determinants of hepatitis C antiviral effectiveness awareness among people who inject drugs in the direct-acting antiviral era.
    Valerio H; McAuley A; Innes H; Palmateer N; Goldberg DJ; Munro A; Taylor A; Hutchinson SJ
    Int J Drug Policy; 2018 Feb; 52():115-122. PubMed ID: 29414462
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Barriers and facilitators for assessment and treatment of hepatitis C virus infection in the opioid substitution treatment setting: insights from the ETHOS study.
    Treloar C; Rance J; Dore GJ; Grebely J;
    J Viral Hepat; 2014 Aug; 21(8):560-7. PubMed ID: 24299222
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association between harm reduction intervention uptake and recent hepatitis C infection among people who inject drugs attending sites that provide sterile injecting equipment in Scotland.
    Allen EJ; Palmateer NE; Hutchinson SJ; Cameron S; Goldberg DJ; Taylor A
    Int J Drug Policy; 2012 Sep; 23(5):346-52. PubMed ID: 22940142
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatitis C virus prevalence and associated risk factors among Indigenous Australians who inject drugs.
    Doyle M; Maher L; Graham S; Wand H; Iversen J
    Aust N Z J Public Health; 2018 Feb; 42(1):52-56. PubMed ID: 29168317
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.